Keenova Announces Publication of XIAFLEX (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie’s disease treated with Xiaflex (collagenase clostridium histolyticum). The Keenova-sponsored posthoc analysis, which evaluated existing Xiaflex clinical trial data, appears in Translational Andrology and Urology.
“These findings highlight the importance of looking beyond pain alone when evaluating Peyronie’s disease. This reinforces that pain and disease duration, while important factors, should not be the sole determinants of treatment timing, but treatment decisions should be grounded in a comprehensive clinical assessment and the evolving understanding of Peyronie’s disease.” – Landon Trost, MD, Director of the Male Fertility and Peyronie’s Clinic in Orem, Utah, and senior author of the study.
Manuscript Details
Title: Peyronie’s Disease Patients With Pain: A Post Hoc Analysis of the IMPRESS I/II Studies
Authors: Jesse N. Mills, MD; Gregory A. Broderick, MD; James P. Tursi, MD; Marian Ayad, PharmD, BCPS; Tina Rezakhani, PharmD, MBA; Jeffrey Andrews, MS; Sajel Patel, PharmD; Landon Trost, MD
